Login / Signup

Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?

Khaled Al SmadiAmmar QureshiBesher AshouriZeid Kayali
Published in: Expert opinion on investigational drugs (2024)
Keyphrases
  • cancer therapy
  • fatty acid
  • phase ii
  • adverse drug
  • cell therapy
  • drug delivery
  • drug administration
  • electronic health record
  • double blind